PURPOSE: The aim of our study is to investigate the mechanism of metastasis, to detect novel metastasis-associated molecules, and to evaluate the molecules from the point of view of clinical application. A monoclonal antibody MH8-11, which we established, recognizes a glycoprotein that is identical to aminopeptidase N (APN/CD13). APN/CD13 degrades the extracellular matrix, while it is also involved in cell motility and improves angiogenesis. EXPERIMENTAL DESIGN: We investigated the expression of APN/CD13 in 194 cases of non-small cell lung cancer (NSCLC) by immunohistochemical analyses and reverse transcription-PCR assay to determine the significance of this prognostic factor; 95 tumors were stage I, 36 were stage II, 39 were stage IIIA, and 24 were stage IIIB. Moreover, we investigated that the relationship between the expression of APN/CD13 and angiogenesis and prognosis for patients with NSCLC. RESULTS: We found a correlation between the expression of APN/CD13 and angiogenesis (r = 0.659; P < 0.0001). In the 194 patients with NSCLC, we found 68 patients to be APN/CD13+ and 126 patients to be APN/CD13-. The 5-year survival rate in patients with APN/CD13+ tumors was significantly lower than in those whose tumors had negative APN/CD13 (48.3% versus 67.1%; P = 0.0001). CONCLUSION: Our data suggest the expression of APN/CD13 for patients with NSCLC to be associated with a poor prognosis and angiogenesis. This is the first study to show the relationship between the expression of APN/CD13 and the prognosis of patients with NSCLC. The inhibition of APN/CD13 may be an effective new molecular target therapy for patients with NSCLC.
PURPOSE: The aim of our study is to investigate the mechanism of metastasis, to detect novel metastasis-associated molecules, and to evaluate the molecules from the point of view of clinical application. A monoclonal antibody MH8-11, which we established, recognizes a glycoprotein that is identical to aminopeptidase N (APN/CD13). APN/CD13 degrades the extracellular matrix, while it is also involved in cell motility and improves angiogenesis. EXPERIMENTAL DESIGN: We investigated the expression of APN/CD13 in 194 cases of non-small cell lung cancer (NSCLC) by immunohistochemical analyses and reverse transcription-PCR assay to determine the significance of this prognostic factor; 95 tumors were stage I, 36 were stage II, 39 were stage IIIA, and 24 were stage IIIB. Moreover, we investigated that the relationship between the expression of APN/CD13 and angiogenesis and prognosis for patients with NSCLC. RESULTS: We found a correlation between the expression of APN/CD13 and angiogenesis (r = 0.659; P < 0.0001). In the 194 patients with NSCLC, we found 68 patients to be APN/CD13+ and 126 patients to be APN/CD13-. The 5-year survival rate in patients with APN/CD13+ tumors was significantly lower than in those whose tumors had negative APN/CD13 (48.3% versus 67.1%; P = 0.0001). CONCLUSION: Our data suggest the expression of APN/CD13 for patients with NSCLC to be associated with a poor prognosis and angiogenesis. This is the first study to show the relationship between the expression of APN/CD13 and the prognosis of patients with NSCLC. The inhibition of APN/CD13 may be an effective new molecular target therapy for patients with NSCLC.
Authors: Gopal Pathuri; Andria F Hedrick; Bryan C Disch; John T Doan; Michael A Ihnat; Vibhudutta Awasthi; Hariprasad Gali Journal: Bioconjug Chem Date: 2011-12-20 Impact factor: 4.774
Authors: Liliana Guzman-Rojas; Roberto Rangel; Ahmad Salameh; Julianna K Edwards; Eleonora Dondossola; Yun-Gon Kim; Alan Saghatelian; Ricardo J Giordano; Mikhail G Kolonin; Fernanda I Staquicini; Erkki Koivunen; Richard L Sidman; Wadih Arap; Renata Pasqualini Journal: Proc Natl Acad Sci U S A Date: 2012-01-17 Impact factor: 11.205
Authors: John D Lapek; Zhenze Jiang; Jacob M Wozniak; Elena Arutyunova; Steven C Wang; M Joanne Lemieux; David J Gonzalez; Anthony J O'Donoghue Journal: Mol Cell Proteomics Date: 2019-01-31 Impact factor: 5.911
Authors: Kristina Viktorsson; Carl-Henrik Shah; Therese Juntti; Petra Hååg; Katarzyna Zielinska-Chomej; Adam Sierakowiak; Karin Holmsten; Jessica Tu; Jack Spira; Lena Kanter; Rolf Lewensohn; Anders Ullén Journal: Mol Oncol Date: 2016-01-02 Impact factor: 6.603
Authors: Åke Berglund; Anders Ullén; Alla Lisyanskaya; Sergey Orlov; Hans Hagberg; Bengt Tholander; Rolf Lewensohn; Peter Nygren; Jack Spira; Johan Harmenberg; Markus Jerling; Carina Alvfors; Magnus Ringbom; Eva Nordström; Karin Söderlind; Joachim Gullbo Journal: Invest New Drugs Date: 2015-11-10 Impact factor: 3.850